The GnRH-ant protocol has received global attention for its simplified treatment course, shortened treatment period, and low incidence of ovarian hyperstimulation syndrome (OHSS) (1, 2). This evidence concerns the gene GNRH1 and ovarian hyperstimulation syndrome.